Decades of Leadership in Oncology
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Takeda Provides Update on EXKIVITY® (mobocertinib)
Discovering and developing innovative therapies to deliver potentially transformative treatments
Hear from Teresa Bitetti, President of the Global Oncology Business Unit, as she discusses how Takeda and its partners are providing cancer care beyond medicine by supporting other areas of patients' lives, such as finances and mental health.